(Q38044043)

English

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

scientific article published on 11 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 August 2017

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study (English)

1 reference

Europe PubMed Central

27 August 2017

0 references

type 2 diabetes

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

9

object named as

D R Matthews

1 reference

Europe PubMed Central

27 August 2017

author name string

M Nauck

1

1 reference

Europe PubMed Central

27 August 2017

A Frid

2

1 reference

Europe PubMed Central

27 August 2017

K Hermansen

3

1 reference

Europe PubMed Central

27 August 2017

A B Thomsen

4

1 reference

Europe PubMed Central

27 August 2017

M During

5

1 reference

Europe PubMed Central

27 August 2017

N Shah

6

1 reference

Europe PubMed Central

27 August 2017

T Tankova

7

1 reference

Europe PubMed Central

27 August 2017

I Mitha

8

1 reference

Europe PubMed Central

27 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

11 October 2012

1 reference

Europe PubMed Central

27 August 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

27 August 2017

15

1 reference

Europe PubMed Central

27 August 2017

3

1 reference

Europe PubMed Central

27 August 2017

204-212

1 reference

Europe PubMed Central

27 August 2017

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12012

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12012

21 January 2018

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12012

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12012

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12012

21 January 2018

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12012

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12012

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12012

21 January 2018

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12012

21 January 2018

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12012

21 January 2018

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12012

21 January 2018

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12012

21 January 2018

Identifiers

10.1111/DOM.12012

1 reference

Europe PubMed Central

27 August 2017

1 reference

Europe PubMed Central

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38044043&oldid=1738339886"